Verizon Makes List Of Military-Friendly Employers and 2 Other Dow Movers to Watch
Verizon Communications Inc. (NYSE:VZ): Current price $49.91
In commemoration of its military recruiting and hiring practices, Verizon has been named to the G.I. Jobs Military-Friendly Employers List for 2014. The giant carrier placed at number 3 on the list, up from 15th in 2013. Verizon employs about 12,000 veterans. Firms on the elite Military-Friendly Employer list were chosen based on a survey of over 5,000 businesses. Criteria for the survey included a benchmark score spanning key programs and policies like the strength of company military recruiting efforts; the percentage of new hires having prior military service; retention programs; and company policies as to National Guard and Reserve service.
3M Co. (NYSE:MMM): Current price $127.84
Corporate Scientist Dr. Andy Ouderkirk for 3M’s Electronics Markets Materials Division has received the 2013 R&D Magazine Innovator of the Year Award, honoring him for demonstrated skills in leadership and innovation. He was cited for excellence in research for inventing advanced optical films that are employed in consumer electronics and furthering practical development processes. Ouderkirk’s research led to the creation of 3M Multilayer Optical Film with light management properties that conserve energy. The thin film is utilized in e-books, smart phones, computer displays, tablets, and other consumer electronics devices to help improve battery life.
Pfizer Inc. (NYSE:PFE): Current price $31.22
Pfizer said on Friday that its organ transplant drug Rapamune has failed in a clinical trial. Rapamune as an immunosuppressant drug was approved to prevent organ rejection in patients who have received a kidney transplant, and is recommended for patients who have just had a transplant. This latest trial compared patients who were treated with an older drug, tacrolimus, to patients who started on tacrolimus and switched to treatment with Rapamune three to five months after their transplant procedure. Pfizer said that patients on both regimens had similar improvements in kidney function.